Table 1 Patient baseline and correlation between NCKAP1 expression and clinicopathologic characteristics in hepatocellular carcinoma (HCC)

From: NCKAP1 improves patient outcome and inhibits cell growth by enhancing Rb1/p53 activation in hepatocellular carcinoma

NCKAP1 expression levels

Clinicopathological variable

No.

Negative

Positive

P value

Age (yr)

   

0.559

≤50

101

57

44

 

>50

79

48

31

 

Gender

   

0.305

Female

19

9

10

 

Male

161

96

65

 

Hepatitis B surface Ag

   

0.682

Negative

15

8

7

 

Positive

165

97

68

 

Serum AFP (ng/mL)

   

0.325

<400

93

51

42

 

≥400

87

54

33

 

Tumor size (cm)

   

0.235

≤5

70

37

33

 

>5

110

68

42

 

Tumor number

   

0.272

Solitary

134

75

59

 

Multiple

46

30

16

 

Microvascular invasion

   

0.217

No

108

59

49

 

Yes

72

46

26

 

PVTT

   

0.916

No

153

89

64

 

Yes

27

16

11

 

Liver cirrhosis

   

0.494

No

48

30

18

 

Yes

132

75

57

 

Differentiation grade

   

0.467

I + II

112

63

49

 

III + IV

68

42

26

 

BCLC stage

   

0.272

0–A

134

75

59

 

B–C

46

30

16

 

TNM stage

   

0.405

I

87

48

39

 

II–IV

93

57

36

 
  1. AFP alpha-fetoprotein, PVTT portal vein tumor thrombus